DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside. ・MacroGenics CEO Eric ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, ...

The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

Stem CentRx posits that cancer is caused by stem cells gone awry - and is developing antibody drug conjugate therapies to help attack cancer at its root. The Peter Thiel-backed "unicorn" startup is ...